Our Long Journey To FDA Approval

By Michael Bailey

The humanity of those we serve in the life sciences is especially important to keep top-of mind today as the financial markets buffet small biotechs with both positive and negative news alike. During these challenging times, CEOs need to remember that we are privileged to pursue such a noble cause that is undiminished by market volatility. The financial markets, though, weren’t the cause of one of the most difficult periods, I faced as CEO of AVEO Oncology. Instead, it was the decade-long journey we took to gain approval of our flagship kidney cancer drug, FOTIVDA (tivozanib), after significant regulatory and organizational setbacks